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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Tartrate-resistant acid phosphatase (TRACP) 5a is expressed strongly in
inflammatory macrophages (MF). Serum TRACP5a is elevated in rheumatoid arthritis patients
with extra-articular manifestations of rheumatoid nodules, in a percentage of patients with
end-stage chronic kidney disease, and may be a risk marker for acute myocardial infarction.
This proof-of-concept study was undertaken in patients with sarcoidosis to further substantiate
our hypothesis that TRACP5a protein is a biomarker for macrophages in other chronic inflam-
matory diseases.
Methods: Immunohistochemical staining for TRACP5a and CD68 was performed in tissues of 19
patientswith sarcoidosis.We alsomeasured circulating TRACP5a protein and other inflammation
biomarkers including interkeukin-6, angiotensin-converting enzyme,andC-reactiveprotein in 13
patients. Twentyhealthy age-matchednonsmoking individualswereusedas the referencegroup.
Results: All sarcoidosis tissues showed strong staining for TRACP5a andCD68 in the non-caseating
granulomatous lesions and localized specifically toMF,multinucleate giant cells, and epithelioid
MF. Serum TRACP5a protein was elevated significantly in active sarcoidosis patients comparedhave no conflicts of interest relevant to this article.
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Tartrate-resistant acid phosphatase 5a in sarcoidosis 365with the control group, and levels fluctuated with disease activity in one patient studied longitu-
dinally.
Conclusion: TRACP5a protein is expressed abundantly in the granulomatous tissues and may be
elevated in a significant proportion of sarcoidosis patients. These findings further support our
hypothesis that serum TRACP5a is derived from systemic inflammatory MF and thereby may be
a biomarker of inflammation for sarcoidosis and also reflect its disease activity.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Sarcoidosis is a chronic granulomatous disease of unknown
etiology with protean systemic manifestations.1 It is char-
acterized by the accumulation in various organs, primarily
the lungs, of T-helper lymphocytes and inflammatory
macrophage (MF) followed by the formation of non-
caseating granulomas. The diagnosis can be challenging. It
is made on the basis of clinical manifestations and histo-
pathological and radiological characteristics after exclusion
of other causes for granulomatous disease. Determining the
extent of the disease and its activity are also based on
clinical, radiological, and cytological evaluation. In Taiwan,
sarcoidosis is believed to be rare and has not been studied
adequately.2 Many practitioners may overlook the possi-
bility of sarcoidosis. The blood level of angiotensin-
converting enzyme (ACE) is often elevated in sarcoidosis
and is often used for evaluation of disease activity.3
However, ACE is not specific for sarcoidosis or for MF.4
Human serum tartrate-resistant acid phosphatase
(TRACP) exists in two distinct isoforms, 5a and 5b,5e7
expressed primarily by cells of monocyte lineage.8e10
TRACP5b is a clinically relevant osteoclast (OC) marker,
which plays an integral part in bone resorption, either as
a means of matrix degradation within OCs7 or as a mecha-
nism for OC migration.11 During bone resorption, TRACP5b
is secreted into the general circulation where it can be
measured specifically in direct relationship to the number
of OC. In contrast, a biological function for TRACP5a has not
yet been determined. TRACP5a is secreted by inflammatory
MF and dendritic cells preferentially, while TRACP5b
remains intracellular. Tissues affected by chronic antigen
stimulation, inflammation, and granulomatous processes
including those of sarcoidosis all contain abundant TRACP-
expressing MF.10,12,13 Furthermore, mean serum TRACP5a
protein is elevated in rheumatoid arthritis (RA) patients
with rheumatoid nodules compared to those without
nodules.14 TRACP5a protein level may also reflect the
inflammatory burden of cardiovascular disease and is
independently associated with acute myocardial infarction
in patients at risk.15 These observations have led to our
hypothesis that circulating TRACP5a is derived from
inflammatory MF in accordance with their systemic number
and is a possible reflection of disease severity.14e16 If this
hypothesis is correct, TRACP5a protein should be increased
in other systemic chronic inflammatory diseases as well.
In this proof-of-concept study, we investigated the
tissue expression and serum levels of TRACP5a in a cohort
of Taiwanese sarcoidosis patients to further substantiate
our hypothesis that serum TRACP5a is a marker of MFburden and relates to its disease severity as with other
chronic inflammatory diseases.Materials and methods
Study participants
Thirteen patientswith sarcoidosis, seen over the period from
March 2007 to December 2009, from whom serum was
available, are included in this study. There were eight
patients in active symptomatic phase, and five of themwere
inactive. Disease activity was determined by symptomatic
granuloma formation, and inactive cases were in resolution
state. One patient (index case)was followed over 22months.
In five patients, a single serum specimen was obtained and
tissue biopsy specimens (eye, neck lymph node and medi-
astinal lymph node) were retrieved for retrospective histo-
logical and immunohistochemical confirmation. In the
remaining eight participants, only serum was available. In
addition to these 13 patients, archive tissues from another
11 patients with sarcoidosis seen at Tri-Service General
Hospital (TSGH) from November 15, 2000 to May 27, 2008,
were included for histological characterization of sarcoid-
osis in Taiwan. These consisted of nine lymph nodes, one
lung, one bone marrow, one liver, one skin, and one eye.
Furthermore, tissue specimens from three patients with
sarcoidosis (2 lymph nodes and 1 liver biopsy) were retrieved
from the archives of the Pathology Department of the
University of Louisville for histological and immunohisto-
logical comparison to sarcoidosis in Taiwan.
Serum was drawn from a healthy age-matched control
group of 20 individuals seen in the health-check clinic of
TSGH from January to December 2007 to establish a refer-
ence range for biomarkers. All specimens and serums from
all study objects were collected after informed consent was
obtained. These studies were conducted in accordance
with the provisions of the Helsinki Declaration and with the
approval of the Human Studies Committee of the TSGH and
the Human Subjects Protection Program Office of the
University of Louisville.
Immunohistochemistry
In addition to routine hematoxylin and eosin stains,
immunohistochemical staining for TRACP and CD68 was
performed according to methods reported previously.12
Briefly, sections were deparaffinized, hydrated, and sub-
jected to heat-induced epitope retrieval by incubation
overnight at 72C in a commercial solution of ethylene-
Figure 1 (A) Lymph node hematoxylin and eosin stain, 10;
(B) TRACP220, 20; (C) CD68, 20.
366 Y.-Y. Wu et al.diamine tetraacetate according to manufacturer’s protocol
(Invitrogen, Carlsbad, CA, USA.). Sections were then
stained for TRACP using mab220, specific for isoform 5a and
for CD68 to identify all MF. Control stains were done by
substituting control mouse ascites for specific antibody. All
immunohistochemical stains were performed in the Special
Procedures Laboratory of the University of Louisville using
an automated robotic stainer (Autostainer; Dako Corp.
Carpinteria, CA) and a commercial peroxidase conjugated
streptavidinebiotin detection system (LSAB2; Dako Corp.).
Interpretation of these specimens was made by one of the
authors (SPS), who is an expert hematopathologist, without
knowledge of clinical information.
Serum TRACP5a immunoassay
Serum TRACP5a protein was determined using the solid-
phase, two-site sandwich immunoassay as previously
described utilizing the TRACP5a-specific monoclonal anti-
body, mab220.17 Captured TRACP5a protein was detected
with a separate peroxidase-conjugated anti-TRACP mono-
clonal antibody (mab162-HRP) and disclosed with 200 mL of
a solution of o-phenylenediamine and H2O2 at room
temperature. The reaction was stopped after 15 minutes
with 50 mL 2 M H2SO4. Calibrators were prepared from serial
dilution of partially purified serum TRACP5a to contain from
5.0 to 0.08 mg/L and run simultaneously. The intra-assay
coefficient of variation is 2.8% and the inter-assay coeffi-
cient of variation is 3.7%.
Other biomarker assays
Serum interleukin-6 (IL-6) was determined using a commer-
cial immunoassay kit according to the manufacturer’s direc-
tions (RayBiotech Inc.) and expressed as pg/mL. Serum C-
reactive protein (CRP) was determined by a high-sensitivity
in-house immunoassay constructed from commercial anti-
bodies and purified human CRP as standard (Dako Corp.) and
expressed as mg/dL. ACE was determined by a kit method
performed according to the manufacturer’s protocol (Bu¨hl-
mann, Inc., Scho¨nenbuch, Switzerland) and expressed as
Unit/L.
Statistical analysis
Reference ranges for biomarker levels were established in
the control group of 20 healthy individuals. Using SPSS
version 12, one-way analysis of variance was used to
compare mean biomarker levels among active and inactive
disease patients and control groups. Follow-up t-tests were
done to identify significant differences in pairwise compar-
isons. Pearson’s correlation was used to estimate the
strength of the relationships between each biomarker pair.
Results
Histopathology of sarcoidosis
Tissues from a total of 19 cases of sarcoidosis, including
three from the United States, were examined to comparethe histological and immunohistochemical characteristics
of the disease in Taiwanese patients to those from the
United States. The 16 cases from TSGH comprised 10 men
and six women. Nine patients had stage I disease, four had
stage II disease, and three had stage III disease defined by
criteria in pulmonary sarcoidosis.1 In all 19 patients, char-
acteristic non-caseating granuloma with multinuclear giant
cells was a prominent feature (Fig. 1A). TRACP5a protein
was strongly and specifically expressed in the inflammatory
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These cells also expressed CD68, confirming their MF origin
(Fig. 1C). In all instances, histological and immunohisto-
chemical features of the Taiwan cases were identical to
those from the United States.
Serum biomarkers in sarcoidosis
Table 1 lists the demographic characteristics of patients
and their serum biomarker levels. Mean baseline values of
all biomarkers, including TRACP5a protein, IL-6, CRP and
ACE were significantly different among sarcoidosis patients
compared with healthy control. Follow-up t-tests identified
that TRACP5a, IL-6 and CRP were elevated only in the
active disease group compared to control. ACE was
elevated significantly in both active and inactive disease
groups compared with the control group (Fig. 2, Table 2).
Significant univariate correlations were present among all
markers pairs except IL-6 versus ACE (Table 3).
Serial study of biomarkers during sarcoidosis
disease evolution (index case)
A 32-year-old Taiwanese woman without a history of
hepatitis was found to have jaundice and tea-colored urine
in January 2007. Physical examination revealed a single,
enlarged, non-tender lymph node on her neck. Computer-
ized tomography (CT) showed abdominal lymphadenopathy
and splenomegaly. Histopathology of the neck lymph node
biopsy revealed benign histiocytic proliferation with no
malignant cells. Dexamethasone and vincristine therapy
was ineffective; her symptoms worsened and her total
bilirubin rose from 8.4 to 10.5 mg/dL (normal <1.5 mg/dL).
In March 2007, she had persistent jaundice, intermittent
low-grade fever, and generalized edema. A biochemistry
profile showed elevated liver function tests and lacticTable 1 Biomarkers level and demographics of sarcoidosis pati
Patient
number
Age Sex Stage FEV1/FVC
(%)
Status DLCO
(%)
Involv
1a 32 Female II 90 Active 77 Bilate
2 55 Female I 84 Active 89 Bilate
3 53 Female II Active Bilate
4 21 Male III 91 Active 67 Bilate
5 88 Female I 79 Inactive 97 Bilate
6 68 Female I 77 Inactive 92 Bilate
7 26 Male II 93 Inactive 92 Bilate
8 33 Male II 72 Inactive 80 Bilate
9 68 Female I 81 Active 78 Bilate
10 58 Female I 80 Active Bilate
11 41 Male I Inactive Bilate
12 62 Female II 79 Active 77 Bilate
13 58 Female I 73 Active Bilate
ACE Z angiotensin-converting enzyme; CRP Z C-reactive protein;
FEV1 Z forced expiratory volume in 1 second; IL-6 Z interleukin-6;
phosphatase 5a protein.
a Index patient.dehydrogenase. A bone marrow biopsy revealed histiocytic
hyperplasia and erythrophagocytosis. Virus-related hemo-
phagocytic syndrome, lysosomal storage disease, or Wil-
son’s disease were considered but eventually ruled out
after assays for b-glucosidase and sphingomyelinase showed
her levels to be within normal limits, and serum cerulo-
plasmin was determined to be 73.2 mg/dL (normal
22e58 mg/dL). A recent cytomegalovirus (CMV) infection
was documented due to a positive IgM and a negative IgG
titer against CMV. EspteineBarr virus IgM was negative. She
received no further treatment but was monitored closely.
She recovered clinically with disappearance of generalized
edema, diminished jaundice, and improved performance
status. A class switch to anti-CMV IgG, with negative IgM, 5
weeks later confirmed CMV infection.
CT on November 1, 2007 showed progressive mediastinal
lymphadenopathy and newly developed multiple subcuta-
neous nodules (Fig. 3A and B). Subcutaneous nodule biopsy
revealed non-caseating granuloma similar to that of
previous biopsies. All of these findings indicated progres-
sion of her underlying histiocytic disorder and were most
compatible with the diagnosis of sarcoidosis. She was
referred to a rheumatologist, and underwent specific
treatment for 8 months including methylprednisolone,
geniquine, and azathioprine until June 2008. A follow-up CT
scan in October 2008 showed significant regression of
mediastinal lymphadenopathy and subcutaneous nodules
(Fig. 3C).
Fig. 4 illustrates changes in serum biomarker levels in
this index case during the evolution of the disease. The MF
markers ACE and TRACP5a were significantly elevated at
baseline. Serum TRACP5a decreased markedly as her
disease responded to methylprednisolone, as evidenced by
the resolution of her mediastinal and subcutaneous lesions
at the 20th month. The inflammation markers IL-6 and CRP
levels were elevated at baseline, but decreased to normal
soon after dexamethasone and vincristine were initiated.ents in this study.
ed site TRACP5a
protein
IL-6 CRP ACE
(ng/mL) (pg/mL) (mg/dL) (U/L)
ral hilar/lung/skin 20.66 172.3 31.46 675.92
ral hilar/eye 11.63 9.2 0.53 205.71
ral hilar and lung 13.67 0.93 0.37
ral lung parenchyma 7.13 1.79 2.16 142.18
ral hilar 7.28 0.64 0.89 95.24
ral hilar 13.31 1.1 0.76 244.56
ral hilar and lung 8.1 23.45 0.21 NA
ral hilar/lung/eye 11.72 0.44 0.3 267.42
ral hilar 12.49 152.12 11.79 112.84
ral hilar and skin 9.6 1.91 14.02 564.64
ral hilar and skin/liver 8.11 1.77 6.91 249.82
ral hilar 6.95 0.3 0.97 133.07
ral hilar and skin 11.19 1.62 4.18 123.97
DLCO Z lung diffusion capacity; FVC Z forced vital capacity;
NA Z not available; TRACP5a protein Z tartrate-resistant acid
Figure 2 Scatter plot of biomarkers compare control, inactive and active sarcoidosis groups.
368 Y.-Y. Wu et al.When CMV infection was detected with positive anti-CMV
IgM, serum IL-6 and CRP level spiked, but rapidly declined
with anti-CMV isotype shift to IgG. Both CRP and IL-6
gradually increased ahead of TRACP5a as the disease pro-
gressed and declined with steroid therapy and disease
improvement. Serum ACE, a traditional marker used in
sarcoidosis, did not track with CRP, IL-6, or TRACP5a during
disease progression and regression. It remained mildly
elevated over the whole clinical course, which might relate
to the residual disease.
Discussion
Sarcoidosis is a systemic granulomatous disease with an
unpredictable clinical course. It is most commonly man-
ifested in lungs, but can involve any assortment of tissuesTable 2 Serum biomarkers’ level among sarcoidosis patients an
Active Inac
n Z 8 n Z
Age 50.8  16.0a 51
TRACP5a protein (ng/mL) 11.66  4.35 9.
IL-6 (pg/mL) 42.52  74.12 5.
CRP (mg/dL) 8.19  10.77 1.
ACE (U/L) 279.76  236.70 214.
a Mean  SD.and organs. The diagnosis of sarcoidosis is one of exclusion
based on clinical, radiological, and characteristic histo-
pathological findings in affected tissues, the hallmark
feature being the presence of non-caseating granuloma
containing epithelioid MF and multinucleated giant cells.
In this study, we have shown high-level immunohisto-
chemical expression of TRACP5a in granulomatous tissues
in sarcoidosis which could be the direct source of serum
TRACP5a. The histopathology of Taiwanese cases was
identical to those from the United States. The strong
expression of TRACP5a in macrophages of sarcoidosis
granuloma extends our previous findings of TRACP5a
expression in activated and inflammatory macrophages of
a variety of chronic inflammatory pathologic tissues.
Sarcoidosis is rare in Taiwan, and the diagnosis is diffi-
cult.2 Biomarkers for diagnosis and monitoring of thed healthy individuals.
tive Control One-way analysis
of variance, p5 n Z 20
.2  26.0 49.9  2.1 0.968
70  2.65 8.04  1.95 0.014
48  10.06 4.88  7.47 0.055
81  2.86 0.54  0.63 0.007
26  79.95 70.82  29.77 0.001
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used but is not disease specific or MF specific.18 TRACP5a
is a novel biomarker of chronic inflammation expressed
and secreted almost exclusively by activated or inflam-
matory MF,8 especially in granulomatous tissues including
sarcoidosis as seen here. This is indeed suggested by our
previous results with RA.14 Our hypothesis is that as the
extent of this pathology reaches a certain threshold,
serum levels of TRACP5a become significantly elevated.
TRACP5a protein is elevated in RA with nodules 14 and in
about one-half of patients on chronic hemodialysis in
whom it correlates with other inflammation markers.19
TRACP5a protein is also elevated in patients having
acute myocardial infarction, suggesting that it may be
a risk marker in cardiovascular disease.15 The eight cases
of active sarcoidosis presented in this study had a signifi-
cant increase in mean TRAP5a, IL-6, CRP, and ACE, and
suggest that variation in TRACP5a and ACE may be related
to the extent of disease. Serum ACE was elevated in all
sarcoidosis patients compared with normal controls, while
TRACP5a became elevated only in active cases. It is
reasonable therefore to postulate that TRACP5a protein,
which represents the amount of macrophages, reflects the
patients’ disease activity. Like ACE, TRACP5a by its nature
cannot be considered as a disease-specific diagnostic
marker, and we do not propose it as such. Instead, we
postulate that serum TRACP5a could be used as a marker
for systemic MF burden and disease severity in a variety
of clinical settings of chronic inflammation including
sarcoidosis. The clinical, biochemical, and histopatho-
logical presentation of the index case, studied longitudi-
nally, was entirely consistent with our hypothesis. The
potential value of TRACP5a in sarcoidosis is illustrated by
our index case, which demonstrated a close correlation
between biomarkers and extent of disease and showed
tissue involvement. Caution must be exercised when
interpreting results from only a single patient followed
longitudinally. It remains to be seen from further study
whether biomarkers, in fact, have a clinical value for
staging sarcoidosis.
Nevertheless, TRACP5a is a MF marker that can
reflect the severity and systemic MF burden of chronic
inflammatory diseases such as sarcoidosis, RA, end-
stage kidney disease, and cardiovascular disease accor
ding to our current and serial studies.14e16 Further study
may be conducted to validate its clinical usefulness
across a broad spectrum of other chronic inflammation
diseases.Table 3 Pearson’s correlation between biomarkers.
IL-6 CRP ACE
(pg/mL) (mg/dL) (U/L)
TRACP5a protein (ng/mL) r 0.732 0.744 0.644
p 0.007 0.006 0.032
IL-6 (pg/mL) r 0.795 0.403
p 0.002 0.219
CRP (mg/dL) r 0.811
p 0.0052
Figure 3 (A) CT scan on March 8, 2007. Enlargement of the
mediastinal lymph nodes; no subcutaneous nodules. (B) CT
scan on November 1, 2007. Progressive enlargement of medi-
astinal lymph nodes and the appearance of subcutaneous
nodules. (C) CT scan on October 30, 2008. Good resolution of
bilateral hilar lesion and subcutaneous nodules after oral
steroids had been taken for 4 months.
Figure 4 Treatment protocol of this patient.
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